Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.

Prodrugs help overcome limitations associated with the parent drug, such as poor solubility, limited permeability, or unfavorable pharmacokinetic properties. By chemically modifying the drug molecule to a prodrug, its absorption, distribution, metabolism, and elimination (ADME) characteristics can be enhanced, leading to improved therapeutic outcomes.

The activation of prodrugs typically occurs through various mechanisms, including enzymatic hydrolysis, oxidation, or reduction, which are inherent biological processes occurring mainly in the liver. In addition, some prodrugs are metabolized at the site of action, while others are transformed extracellularly in blood or gastrointestinal fluids.

Prodrugs offer several advantages in drug development. They can extend the life of a drug and can also enhance patient compliance by offering alternative routes of administration or reducing the frequency of dosing. They have been employed to target specific tissues or cells by utilizing site-specific enzymes or transporters, minimizing off-target effects. As a result, prodrugs offer improved drug efficacy, better safety, and patient convenience.

Tags
ProdrugsBiotransformationPharmacologically Active DrugTherapeutic PropertiesBioavailabilityStabilityToxicityChemical StructureSolubilityPermeabilityPharmacokinetic PropertiesAbsorptionDistributionMetabolismElimination ADMEEnzymatic HydrolysisDrug DevelopmentPatient Compliance

Du chapitre 3:

article

Now Playing

3.29 : Prodrugs

Pharmacokinetics

2.1K Vues

article

3.1 : Pharmacocinétique : Vue d’ensemble

Pharmacokinetics

3.5K Vues

article

3.2 : Mécanisme d’absorption du médicament : transport membranaire passif

Pharmacokinetics

3.0K Vues

article

3.3 : Mécanisme d’absorption du médicament : transport membranaire médié par le transporteur

Pharmacokinetics

3.0K Vues

article

3.4 : Absorption des médicaments : facteurs affectant l’absorption gastro-intestinale

Pharmacokinetics

3.3K Vues

article

3.5 : Biodisponibilité : Vue d’ensemble

Pharmacokinetics

2.1K Vues

article

3.6 : Facteurs influençant la biodisponibilité : élimination au premier passage

Pharmacokinetics

5.5K Vues

article

3.7 : Bioéquivalence : Vue d’ensemble

Pharmacokinetics

763 Vues

article

3.8 : Effet de premier passage

Pharmacokinetics

4.5K Vues

article

3.9 : Évolution temporelle de l’effet du médicament

Pharmacokinetics

1.7K Vues

article

3.10 : Distribution du médicament : liaison tissulaire

Pharmacokinetics

2.3K Vues

article

3.11 : Barrières physiologiques

Pharmacokinetics

3.1K Vues

article

3.12 : Distribution du médicament : liaison aux protéines plasmatiques

Pharmacokinetics

3.1K Vues

article

3.13 : Modèles à compartiments : Modèle à compartiment unique

Pharmacokinetics

1.9K Vues

article

3.14 : Modèles à compartiments : Modèle à deux compartiments

Pharmacokinetics

4.6K Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.